Trends in penicillin dispensing during an acute rheumatic fever prevention programme

N Z Med J. 2023 Dec 1;136(1586):84-93. doi: 10.26635/6965.6285.

Abstract

Aim: Acute rheumatic fever (ARF), a serious inflammatory condition, often leads to rheumatic heart disease (RHD). Between 2011 and 2016, Aotearoa New Zealand implemented a rheumatic fever prevention programme (RFPP) to reduce high rates of ARF through improved community access to timely diagnosis and early treatment of group A streptococcal (GAS) pharyngitis, which has been shown to prevent subsequent ARF. This study aimed to quantify the change in penicillin antibiotic dispensing rates among children aged 18 years or younger during the RFPP.

Method: This retrospective analysis utilised administrative data from the National Pharmaceutical Collection. Using a controlled, interrupted time series analysis, the effect of the RFPP on antibiotic dispensing rates was explored. Poisson regression models were used to assess the change in dispensing rates during the RFPP among control regions (those not in the RFPP) and regions participating in the RFPP. The primary measure was rate ratio (RR) for the difference between the observed versus counterfactual rates of penicillin dispensing.

Result: A total of 12,154,872 dispensing records between 2005 and 2018 were included. Amoxicillin was the most frequently dispensed penicillin (57.7%), followed by amoxicillin-clavulanate (23.4%). Amoxicillin dispensing increased by 4.3% in regions operating the RFPP compared to the increase in control regions (p<0.001). The overall rate of penicillin dispensing decreased, driven by a rapid decline in amoxicillin-clavulanate dispensing.

Conclusion: During the RFPP an increase in amoxicillin dispensing was seen in regions participating in the programme and regions outside of the programme, indicating the programmatic approach led to improved adherence to recommended first-line antibiotics.

MeSH terms

  • Amoxicillin
  • Amoxicillin-Potassium Clavulanate Combination
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Humans
  • New Zealand
  • Penicillins / therapeutic use
  • Retrospective Studies
  • Rheumatic Fever* / drug therapy
  • Rheumatic Fever* / prevention & control
  • Rheumatic Heart Disease*

Substances

  • Penicillins
  • Anti-Bacterial Agents
  • Amoxicillin
  • Amoxicillin-Potassium Clavulanate Combination